Skip to main content

Cellectis Bioresearch Establishes US Subsidiary

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis bioresearch today announced it has created a US subsidiary.

The US subsidiary is called Cellectis bioresearch Inc., and is headquartered at the Cambridge Innovation Center in Cambridge, Mass. Cellectis bioresearch, based in Romainville, France, is a subsidiary of Cellectis, and provides tools for genome customization.

The US company will be responsible for promoting Cellectis bioresearch products and services in the US. Eric Merle has been named sales director for the US and will be in charge of recruiting and managing a sales staff. He will report to Luc Selig, vice president of sales and marketing at the French operations.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.